ArticleCancers2023

Efficacy and Safety of First-Line Cytokines versus Sunitinib and Second-Line Axitinib for Patients with Metastatic Renal Cell Carcinoma (ESCAPE Study): A Phase III, Randomized, Sequential Open-Label Study.

Yoshifumi Kadono et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.